Alternative treatment options include docetaxel-cyclophosphamide for the early stages of HR(+) BC and TNBC, Tb-CTx and dual HER2 targeting agents for HER2(+) disease, and carboplatin plus docetaxel for TNBC [32,33,34,35]. This evidence concerns the gene ERBB2 and breast cancer.